Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The Food and Drug Administration (FDA) added a "black box" warning in 2004 to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) advising that prolonged use might result in bone mineral density loss.

DMPA: Time to repeal black box warning?